Hospital Profile
Name | Mayo Regional Hospital |
---|
Type | Critical Access Hospital |
---|
Location | 897 West Main Street, Dover Foxcroft, Maine |
---|
Ownership | Government - Hospital District or Authority |
---|
Emergency Services | Yes |
---|
Medicare ID (CCN) | 201309 |
Patients' Experience Survey:
Overall Rating of the Hospital:
Willingness to Recommend Hospital:
Yes Patients who reported YES, they would definitely recommend the hospital
Probably Patients who reported YES, they would probably recommend the hospital
No Patients who reported NO, they would probably not or definitely not recommend the hospital
Cleanliness of Hospital Environment:
Always Patients who reported that their room and bathroom were "Always" clean
Usually Patients who reported that their room and bathroom were "Usually" clean
Sometimes or Never Patients who reported that their room and bathroom were "Sometimes" or "Never" clean
Quietness of Hospital Environment:
Always Patients who reported that the area around their room was "Always" quiet at night
Usually Patients who reported that the area around their room was "Usually" quiet at night
Sometimes or Never Patients who reported that the area around their room was "Sometimes" or "Never" quiet at night
Always Patients who reported that their nurses "Always" communicated well
Usually Patients who reported that their nurses "Usually" communicated well
Sometimes or Never Patients who reported that their nurses "Sometimes" or "Never" communicated well
Always Patients who reported that their doctors "Always" communicated well
Usually Patients who reported that their doctors "Usually" communicated well
Sometimes or Never Patients who reported that their doctors "Sometimes" or "Never" communicated well
Responsiveness of Hospital Staff:
Always Patients who reported that they "Always" received help as soon as they wanted
Usually Patients who reported that they "Usually" received help as soon as they wanted
Sometimes or Never Patients who reported that they "Sometimes" or "Never" received help as soon as they wanted
Communication about Medicines:
Always Patients who reported that staff "Always" explained about medicines before giving it to them
Usually Patients who reported that staff "Usually" explained about medicines before giving it to them
Sometimes or Never Patients who reported that staff "Sometimes" or "Never" explained about medicines before giving it to them
Yes Patients who reported that YES, they were given information about what to do during their recovery at home
No Patients who reported that NO, they were not given information about what to do during their recovery at home
Always Patients who "Strongly Agree" they understood their care when they left the hospital
Usually Patients who “Agree” they understood their care when they left the hospital
Sometimes or Never Patients who “Disagree” or “Strongly Disagree” they understood their care when they left the hospital
NPI Associated with the Hospital:
Unlike individual providers, Hospitals may have multiple NPI numbers for example, there can be a separate NPI for each unit within the hospital. We have found possible NPI number/s associated with Mayo Regional Hospital from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.
NPI Number | 1558319103 |
Organization Name | MRH CORP. |
Doing Business As | MAYO REGIONAL HOSPITAL |
Address | 897 W Main St, Dover Foxcroft, ME 04426 |
Hospital Type | General Acute Care Hospital - Critical Access |
Phone Number | 207-564-8401 |
News Archive
All Canadian provinces except Quebec announce funding agreement for PNH drug, Soliris
L'Association Québécoise de l'HPN regrets that Quebec remains one of the only jurisdictions in the developed world to decline including the only effective life-saving treatment against an ultra-rare blood disease - paroxysmal nocturnal hemoglobinuria (PNH) - on its public drug insurance plan drugs list.
SLU selected to work on universal flu vaccine project
Supported by a federal contract, Saint Louis University will study a concept for a universal flu vaccine that is designed to protect people from influenza pandemics that could turn deadly as well as seasonal flu caused by the influenza A virus.
Cytokeratins 8 and 18 can strongly enhance breast cancer drug fulvestrant's anti-estrogenic activity
Women's responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, Indiana University Bloomington scientists report in this month's Cancer Biology & Therapy.
Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO
Cell Therapeutics, Inc. and Chroma Therapeutics Ltd. announced that interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) were presented by Jorge Cortes, M.D. and discussed at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) by Farhad Ravandi, M.D., who presided over the ASCO discussion session, both of the University of Texas M.D. Anderson Cancer Center.
Read more Medical News
› Verified 6 days ago
Structural Quality Measures:
Able to receive lab results electronically | No |
Able to track patients' lab results, tests, and referrals electronically between visits | No |
News Archive
All Canadian provinces except Quebec announce funding agreement for PNH drug, Soliris
L'Association Québécoise de l'HPN regrets that Quebec remains one of the only jurisdictions in the developed world to decline including the only effective life-saving treatment against an ultra-rare blood disease - paroxysmal nocturnal hemoglobinuria (PNH) - on its public drug insurance plan drugs list.
SLU selected to work on universal flu vaccine project
Supported by a federal contract, Saint Louis University will study a concept for a universal flu vaccine that is designed to protect people from influenza pandemics that could turn deadly as well as seasonal flu caused by the influenza A virus.
Cytokeratins 8 and 18 can strongly enhance breast cancer drug fulvestrant's anti-estrogenic activity
Women's responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, Indiana University Bloomington scientists report in this month's Cancer Biology & Therapy.
Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO
Cell Therapeutics, Inc. and Chroma Therapeutics Ltd. announced that interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) were presented by Jorge Cortes, M.D. and discussed at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) by Farhad Ravandi, M.D., who presided over the ASCO discussion session, both of the University of Texas M.D. Anderson Cancer Center.
Read more News
› Verified 6 days ago